William Blair Estimates MaxCyte’s Q2 Earnings (NASDAQ:MXCT)

MaxCyte, Inc. (NASDAQ:MXCT) – Equities researchers at William Blair reduced their Q2 2025 EPS estimates for MaxCyte in a research report issued on Thursday, May 8th. William Blair analyst M. Larew now forecasts that the company will earn ($0.11) per share for the quarter, down from their previous forecast of ($0.09). The consensus estimate for MaxCyte’s current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte’s Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.42) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.39) EPS.

A number of other research firms have also commented on MXCT. Stifel Nicolaus decreased their price objective on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 12th. BTIG Research set a $6.00 price objective on shares of MaxCyte and gave the stock a “buy” rating in a research note on Wednesday, March 12th.

MaxCyte Price Performance

MXCT stock opened at $2.20 on Monday. MaxCyte has a 12 month low of $2.19 and a 12 month high of $5.26. The firm has a market cap of $233.90 million, a PE ratio of -6.47 and a beta of 1.38. The firm has a 50 day simple moving average of $2.78 and a 200 day simple moving average of $3.60.

MaxCyte (NASDAQ:MXCT) last released its earnings results on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The business had revenue of $10.39 million during the quarter, compared to analyst estimates of $9.05 million.

Hedge Funds Weigh In On MaxCyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its stake in MaxCyte by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company’s stock worth $93,000 after purchasing an additional 2,154 shares during the period. Rhumbline Advisers boosted its stake in shares of MaxCyte by 1.6% during the 4th quarter. Rhumbline Advisers now owns 153,655 shares of the company’s stock valued at $639,000 after buying an additional 2,402 shares during the period. Valmark Advisers Inc. boosted its stake in shares of MaxCyte by 2.2% during the 4th quarter. Valmark Advisers Inc. now owns 115,654 shares of the company’s stock valued at $481,000 after buying an additional 2,478 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of MaxCyte by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,929 shares of the company’s stock valued at $249,000 after buying an additional 2,584 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of MaxCyte by 8.5% during the 4th quarter. Invesco Ltd. now owns 49,096 shares of the company’s stock valued at $204,000 after buying an additional 3,848 shares during the period. Institutional investors and hedge funds own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.